#China #Shenzhen #MGI Tech #DNBSEQ-T1+ #CE Mark

MGI Tech Achieves CE Marking for DNBSEQ-T1+

On June 20, 2025, MGI Tech Co., Ltd., a company dedicated to the development of innovative tools and technologies in the life sciences sector, announced that its latest medium-throughput sequencer, the DNBSEQ-T1+ (referred to as T1+), has received CE marking. This certification enables the T1+ to enter the European market for both research and clinical applications, marking a significant milestone in its global expansion efforts.

The T1+ was first showcased during the AGBT 2025 conference this year, where it captured considerable attention as a flagship benchtop sequencing system designed for delivering medium-performance sequencing capabilities. It is capable of performing 150bp paired-end sequencing runs in just 24 hours with an impressive accuracy of Q40, positioning it as one of the fastest medium-performance sequencers globally, equipped with industry-leading sequencing speed.

In addition to its rapid sequencing capabilities, the T1+ stands out for its versatility, featuring three flow cell formats and two to four addressable lanes per flow cell. This allows for a data throughput range of 25 to 1,200 Gb, making it an ideal solution for researchers aiming to conduct multiple independent experiments on a single platform. This adaptability significantly enhances both lab efficiency and flexibility.

Moreover, the T1+ includes integrated DNB generation and loading systems, as well as a built-in bioinformatics module, which streamline the user experience through simplified workflows. This advanced technology supports a wide array of genomic applications, providing users with a seamless sequencing experience that boosts productivity across various research endeavors.

Duncan Yu, the president of MGI, stated that 'the CE marking confirms that the T1+ is fully compliant with EU standards and regulations for research and clinical applications.' He added, 'We believe that the market introduction of the T1+ holds great promise for advancing genomics, enabling researchers and clinicians in the EU to make strides in areas like precision medicine and oncology through its precise, effective, and versatile sequencing capabilities.'

The T1+ was initially introduced at the ESHG conference this year, where it attracted interest from attendees eager to explore its practical applications. This reception underscores the growing recognition of MGI Tech as a leader in the life sciences sector.

About MGI Tech

Founded in 2016, MGI Tech Co., Ltd. is committed to creating core tools and technologies that foster innovation in life sciences. Our focus encompasses the research, development, manufacturing, and sale of instruments, reagents, and associated products in the realms of life sciences and biotechnology. We offer real-time, multi-omic, full-spectrum digital equipment and systems for precision medicine, agriculture, healthcare, and numerous other fields, reaching clients across all six continents.

MGI is among the few companies capable of autonomously developing and producing clinical-grade gene sequencers, with throughput capabilities ranging from gigabases to terabases. By leveraging unmatched expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the future of life sciences.

For more information, visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.